SG11202104857PA - Heterocyclic spiro-compounds as am2 receptor inhibitors - Google Patents

Heterocyclic spiro-compounds as am2 receptor inhibitors

Info

Publication number
SG11202104857PA
SG11202104857PA SG11202104857PA SG11202104857PA SG11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA SG 11202104857P A SG11202104857P A SG 11202104857PA
Authority
SG
Singapore
Prior art keywords
compounds
receptor inhibitors
heterocyclic spiro
spiro
heterocyclic
Prior art date
Application number
SG11202104857PA
Other languages
English (en)
Inventor
Gareth Richards
Timothy Skerry
Josephy Harrity
Jean-Olivier Zirimwabagabo
Matthew Tozer
Karl Gibson
Roderick Porter
Paul Glossop
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield filed Critical Univ Sheffield
Publication of SG11202104857PA publication Critical patent/SG11202104857PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202104857PA 2018-11-15 2019-11-15 Heterocyclic spiro-compounds as am2 receptor inhibitors SG11202104857PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1818651.0A GB201818651D0 (en) 2018-11-15 2018-11-15 Compounds
PCT/GB2019/053236 WO2020099882A1 (fr) 2018-11-15 2019-11-15 Composés spiro hétérocycliques constituant des inhibiteurs du récepteur de l'am2

Publications (1)

Publication Number Publication Date
SG11202104857PA true SG11202104857PA (en) 2021-06-29

Family

ID=64740129

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104857PA SG11202104857PA (en) 2018-11-15 2019-11-15 Heterocyclic spiro-compounds as am2 receptor inhibitors

Country Status (11)

Country Link
US (1) US20220023281A1 (fr)
EP (1) EP3880679A1 (fr)
JP (1) JP2022507561A (fr)
KR (1) KR20210102261A (fr)
CN (1) CN113227091A (fr)
AU (1) AU2019380715A1 (fr)
BR (1) BR112021009381A8 (fr)
CA (1) CA3119882A1 (fr)
GB (1) GB201818651D0 (fr)
SG (1) SG11202104857PA (fr)
WO (1) WO2020099882A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
GB201818649D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004273057C1 (en) * 2003-09-08 2011-06-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
JP2008512459A (ja) * 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド アリールスピロラクタムｃｇｒｐ受容体拮抗薬
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CA2683581A1 (fr) * 2007-04-11 2008-10-23 Merck & Co., Inc. Antagonistes du recepteur cgrp comprenant des groupes terminaux amide tertiaire, sulfamide, carbamate et uree
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2009034028A2 (fr) * 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh Nouveaux composés
KR20090033583A (ko) * 2007-10-01 2009-04-06 주식회사 엘지생명과학 글라이신 아릴 아마이드를 포함하는 신규한베타-세크리타제 저해용 화합물
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2010107809A2 (fr) * 2009-03-17 2010-09-23 Forest Laboratories Holdings Limited Procédés de préparation de composés inhibiteurs de la dpp-iv
EP2531502B1 (fr) 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phényl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-méthyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phényl]-urée et composés associés, et leur utilisation dans des traitements
JP2014148491A (ja) * 2013-02-04 2014-08-21 Kowa Company Ltd Ｔｌｒ阻害作用を有するチアゾール誘導体
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN107567438B (zh) * 2015-03-03 2021-06-29 拜尔哈文制药股份有限公司 利鲁唑前药及其用途
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
GB201818649D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds

Also Published As

Publication number Publication date
EP3880679A1 (fr) 2021-09-22
KR20210102261A (ko) 2021-08-19
AU2019380715A1 (en) 2021-06-10
GB201818651D0 (en) 2019-01-02
CA3119882A1 (fr) 2020-05-22
BR112021009381A2 (pt) 2021-08-10
JP2022507561A (ja) 2022-01-18
WO2020099882A1 (fr) 2020-05-22
CN113227091A (zh) 2021-08-06
BR112021009381A8 (pt) 2022-03-22
US20220023281A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
IL276509A (en) Heterocyclic compounds as kinase inhibitors
ZA202003778B (en) Heterocyclic compounds as prmt5 inhibitors
IL283333A (en) Heterocyclic compounds
IL273428B1 (en) Heterocyclic compounds as pad inhibitors
IL277455A (en) History of aminopyrimidines as CTPS1 inhibitors
IL280821A (en) Heterocycline compound
SG11202013016YA (en) Heterocyclic compounds as trk inhibitors
SG11202005112TA (en) Heterocyclic compounds as prmt5 inhibitors
IL289617A (en) Heterocyclic compounds
IL289595A (en) Heterocyclic compounds
ZA202104402B (en) Heterocyclic compound
SG11202104883TA (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
SG11202104857PA (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
EP3693360C0 (fr) Composés hétérocycliques
SG11202009356RA (en) Heterocyclic compound
EP3347357A4 (fr) Inhibiteurs des kinases de la famille des kinases tec hétérocycliques
IL277340A (en) The orthocyclic compound
GB201808580D0 (en) Heterocyclic compounds
GB201806488D0 (en) Heterocyclic TADF compounds